Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma by M. Magni et al.
  
Introduction 
 
Malignant lymphoma is the most common he-
matologic malignancy encountered in the West-
ern world [1]. Although progress has been made 
in the treatment of advanced stage lymphomas, 
the majority of patients ultimately relapse. In 
this context, myeloablative therapy followed by 
autologous hematopoietic progenitor cell rescue 
has an established role in the management of 
the disease [2]. In clinical practice, autologous 
transplantation of PBPCs is preferred to autolo-
gous bone marrow transplantation (ABMT) be-
cause it produces a significant improvement in 
the therapeutic index of high-dose chemother-
apy, reducing iatrogenic toxicity [3]. The role for 
purging in ABMT for patients with NHL was sug-
gested by studies that strongly indicated the 
contribution of residual lymphoma cells to re-
lapse [4]. In this regard, clinical programs have 
been developed to assess the usefulness of in 
vitro and in vivo purging procedures also when 
using PBPCs, and lately in vivo purging has been 
described as a promising therapeutic strategy 
[5]. 
 
BM and PB involvement by lymphoma has tradi-
tionally been detected by morphologic and im-
munophenotypic analysis. In the last few years, 
molecular biology techniques have been used 
for detection of MRD with the aim to provide 
prognostic indications. In this context, studies 
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ing the molecular status of PBPCs is still an open issue. Here we report data about MRD analysis in BM, PB and 
PBPCs in a series of mantle cell and indolent NHL patients who underwent high-dose chemotherapy: discordant re-
sults were obtained comparing PB, BM and PBPC molecular data. In addition, differences were noted among these 
results if molecular analysis was performed using well-known rearrangements (i.e., bcl-1/IgH and bcl-2/IgH) or pa-
tient specific oligonucleotides. We conclude that neither BM nor PB are reliable in predicting the molecular status of 
PBPCs and that caution must be adopted in interpreting molecular data obtained using patient specific oligonucleo-
tides. 
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have been performed to find out whether BM 
and PB are equivalent as tissue sources to de-
tect residual disease [6]. The results have 
clearly shown that detection of residual lym-
phoma cells in BM after therapy is associated 
with decrease in disease-free survival [7]. Thus, 
it has been concluded that BM is more informa-
tive than PB in detecting MRD both at the time 
and after ABMT [6].  
 
With the aim to evaluate the usefulness of PB 
and BM PCR analysis to predict the molecular 
status of PBPCs and thus prospectively guide 
their harvest, we recently analyzed these three 
hemopoietic compartments in a series of 30 
NHL patients. Our data show a lack of absolute 
concordance in the detection of residual lym-
phoma cells in PB, BM and PBPCs, assessed by 
PCR using well known chromosomal transloca-
tion (e.g. bcl-2/IgH and bcl-1/IgH) or allele-
specific oriented oligonucleotides based on pa-
tient CDRIII sequences. Although preliminary, 
our results seem to indicate that caution must 
be adopted in assuming that molecular data 
obtained from PB or BM are equivalent to those 
obtained from PBPCs and that the type of the 
molecular marker used during the PCR analysis 
has to be taken into account evaluating the 
data. 
 
Patients and methods 
 
Patients and treatment plan 
 
Between December 1996 and March 2001, 30 
consecutive patients with mantle cell and indo-
lent NHL received high-dose sequential chemo-
therapy with autologous PBPC support and ri-
tuximab (R-HDS). Eligibility criteria included writ-
ten informed consent; age ≤60 years; absence 
of severe organ disfunctions not due to tumor; 
no prior viral infections (HBV, HCV, HIV); a his-
tologically confirmed diagnosis of mantle cell 
lymphoma or follicular lymphoma, either refrac-
tory to or relapsed within one year following first
-line polychemotherapy, and requiring treat-
ment; expression of CD20 by lymphoma cells; 
and availability of a molecular probe for PCR 
amplification of DNA. 
 
All patients received chemotherapy based on 
the treatement plan as already described in 
detail [5]. Briefly, after an initial standard-dose 
phase consisting of 2 to 3 cycles of either 
doxorubicin- or cisplatin-containing chemother-
apy, all patients were assigned to receive a ri-
tuximab-supplemented 4-step high-dose se-
quence including intravenous administration of: 
high-dose cyclophosphamide (7g/m2), high-dose 
cytarabine (2 g/m2 every 12 hours for 6 con-
secutive days), high-dose melphalan (180 mg/
m2), and high-dose mitoxantrone plus melpha-
lan (60 and 180 mg/m2, respectively). Rituxi-
mab was infused intravenously for a total of 6 
doses, twice after cyclophosphamide, twice af-
ter cytarabine, and twice after the final myeloab-
lative step. 
 
Timing, harvesting, and processing of PBPC 
 
Timing and number of collections was prospec-
tively guided by real-time assessment of circu-
lating PBPC counts [8], as well as by results of 
overnight PCR analysis on a sample of har-
vested cells. PBPCs were assessed by counting 
total CD34+ cells by direct immunofluorescence 
flow cytometry (FACS) with the phycoerythrin-
conjugated HPCA-2 CD34 antibody (Becton 
Dickinson, San Jose, CA) as previously de-
scribed [9]. 
 
PBPC harvests were performed during growth-
factor expanded mobilization of progenitor cells 
occurring after either high-dose cyclophos-
phamide, or high-dose cytarabine, or both. 
Mononuclear cells were collected by use of an 
automated leukapheresis system (SPECTRA 
AutoPBSC, COBE, Lakewood, CO), as previously 
described [10]. 
 
BM, PB and PBPC samples preparation 
 
BM and PB samples were obtained from all the 
30 patients at the time of the initial evaluation 
and on the day of PBPC harvest after high-dose 
cyclophosphamide. PBPC samples were col-
lected at the end of each harvest. Samples 
preparation was carried out by alkaline lysis of 
red cells by ACK lysing buffer [11] (ACK, 
BioWhittaker, Walkersville, MD, U.S.A.) and DNA 
extraction performed using the QIAamp DNA 
blood extraction kit (Qiagen, Valencia, CA, 
U.S.A.). 
 
PCR amplification 
 
Molecular monitoring of MRD was performed by 
analyzing DNA samples from PB, BM and PBPCs 
with use of either nested PCR amplification of 
bcl-2/IgH translocation or semi-nested amplifi-
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cation of bcl-1/IgH and clonal rearrangement of 
IgH genes, essentially as already described [12, 
13]. Briefly, for bcl-2/IgH translocation, amplifi-
cation of major (MBR) and minor (mcr) was per-
formed using oligonucleotide primers originally 
designed by Gribben [14], while bcl-1/IgH trans-
location was detected using the primers already 
described by Rimokh [15]. Tumor VDJ was am-
plified using consensus VH.D and JH.D primers 
already designed by Deane [16] (FR1 primers). 
Amplified DNA was directy sequenced using 
VH.D and JH.D primers and VH-, D-, JH- regions 
and N-inserts were identified by BLAST. The 
CDRIII region was identified as the junction of 
these three regions including the N-inserts. 
20mer antisense allele-specific oligonucleotides 
(ASO) primers were designed from the CDRIII 
regions including N-insert. DNA from the patient 
samples was amplified by semi-nested PCR: the 
first amplification used the relevant VH.D family 
and JH.D consensus primers, while the second 
amplification was performed with the same 
VH.D primer and the designed ASO antisense 
primer. Amplified DNAs were analyzed by elec-
trophoresis on 1.5% agarose gels containing 
ethidium bromide and visualized by UV light.  
 
Flow cytometry 
 
Cells from PB were stained for 30 minutes on 
ice with combinations of saturating amounts of 
fluorescein isothiocyanate (FITC)-conjugated or 
phycoerythrin (PE)-conjugated monoclonal anti-
bodies. FITC- or PE-conjugated antibodies 
against CD5, CD19 and CD23 were purchased 
from Becton Dickinson (San Jose, CA, U.S.A.). 
Each fluorescence analysis included appropri-
ate PE- and FITC-conjugated negative isotype 
controls. The percentage of positive cells was 
determined by subtracting the percentage of 
fluorescent cells in the control from the percent-
age of cells positively stained with the appropri-
ate antibody. The cells were analyzed by using a 
FACScan laser flow cytometry system (Becton 
Dickinson) equipped with a Macintosh Power-
Mac G3 personal computer (Apple Computer, 
Cupertino, CA, U.S.A.) and Cell Quest (Becton 
Dickinson) software. 
 
Sensitivity and specificity 
 
The sensitivity of detection of MRD was as-
sessed by PCR amplification of 10-fold serial 
dilutions of tumor cell DNA into normal donor 
PB DNA. The limit of detection of MRD was re-
producible at the level of 10-6 for the bcl-2/IgH 
translocation and at 10-5 for the other two rear-
rangements. A patient-specific positive control 
was included in all PCR reaction; negative con-
trols containing 1) water instead of DNA and 2) 
polyclonal DNAs were added. To further test 
sensitivity, every and each amplification con-
tained a weak-positive, patient-specific control 
consisting of a 10-5 to 10-6 dilution of tumor cell 
DNA into normal donor PB DNA; the reaction 
was thus considered as adequately sensitive 
only if this latter sample gave a positive signal. 
All PCR reactions were performed in duplicate, 
in at least two independent experiments. 
 
Specificity was determined by using the diag-
nostic sample as positive control and BM sam-
ples from three other patients as negative con-
trols. 
 
Results 
 
Patient characteristics 
 
The main characteristics of the 30 NHL patients 
analyzed are listed in Table 1. Histologic find-
ings confirmed the diagnosis of follicular or 
mantle cell lymphoma in all the patients; the 
diagnosis of this latter group was confirmed by 
expression of CD5 and lack of co-expression of 
CD23 on the tumor cells. Bcl-2/IgH rearrange-
ment was detected in 10 out of 21 follicular 
lymphoma patients, and bcl-1/IgH rearrange-
ment was present in 5 out of 9 mantle cell lym-
phoma cases. The majority of patients were 
diagnosed as stage IV disease. 
Detection of lymphoma cells in BM and PB at 
diagnosis 
 
Routine morphological assessment and immu-
nohistochemical staining of BM sections with 
Table 1. Patient characteristics 
Characteristic # 
Histologic findings   
Follicular, grade 1 15 
Follicular, grade 2 2 
Follicular, grade 3 4 
Mantle cell disease 9 
Molecular rearrangement 
Bcl-2/IgH 10 
Bcl-1/IgH 5 
IgH 15 
Stage   
III 7 
IV 23 
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anti-CD3 and anti-CD20 antibodies were per-
formed in all 30 cases at diagnosis. The evalua-
tion of BM by these techniques allowed to iden-
tify lymphoma cells in 20 out of 30 patients 
(66%). Conversely, molecular analysis detected 
lymphomatous involvement in 27 samples ana-
lyzed (90%) (Table 2).  
 
PB was also evaluated: PCR showed lymphoma-
tous involvement in 27 out of 30 patients 
(90%). In addition, in mantle cell lymphoma pa-
tients flow cytometry allowed to detect circulat-
ing lymphoma cells (CD5+/CD19+/CD23-) in 7 
out of 9 patients (78%) (Figure 1A), while in the 
same group, molecular analysis gave evidence 
of a monoclonal population in 9 out of 9 cases 
evaluated (Figure 1B). 
 
Comparison of PBPC harvest, PB and BM PCR 
analysis 
 
To assess the role of BM and PB data obtained 
by PCR analysis in predicting the molecular 
status of PBPCs, samples of the former com-
partments collected at the time of PBPC harvest 
were analyzed together with the latter. As shown 
in Table 3, in 4 out of 13 patients (30%) whose 
BM scored positive at PCR analysis, PBPCs were 
found to be negative. In the remaining 17 pa-
tients, PCR analysis was unable to detect lym-
phoma cells in BM: however, contaminating 
lymphoma cells were detected by PCR in the 
PBPCs of 5 of these patients (29%).  
Table 2. Histological and molecular analysis of 
BM and PB at diagnosis 
Pt BM 
hist 
BM 
PCR 
PB 
PCR 
probe 
1 + + +   
2 + + +   
3 + + +   
4 + + +   
5 - + + bcl2 
6 + + +   
7 + + +   
8 + + +   
9 + + +   
10 + + +   
11 - + +   
12 + + +   
13 - + +   
14 - + +   
15 + + +   
16 - - - IGH 
17 + + +   
18 + + +   
19 - + +   
20 - - -   
21 - - -   
22 + + +   
23 + + +   
24 + + + bcl1 
25 + + +   
26 + + +   
27 - + +   
28 + + +   
29 + + + IGH 
30 - + +   
Neg: -; Pos: + 
 
Figure 1. FACS and 
PCR analysis of PB in 
mantle cell lymphoma 
patients at diagnosis. 
A: flow cytometric char-
acterization of PB; dot 
plots show the CD5/
CD19 distribution of B-
lymphocytes; B: PCR 
analysis of PB; pts 22 – 
26 were analyzed by 
bcl-1/IgH rearrange-
ment, pts 27 – 30 were 
analyzed by CDR3-
based oligonucleotides; 
MW, molecular weight 
standards; (+), positive 
control; (-), no DNA. 
Samples were analyzed 
on 1.5% agarose gel 
and stained with 
ethidium-bromide. 
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Molecular analysis of PB was performed on trip-
licate samples from each patient, immediately 
before PBPC harvest. As shown in Table 3, a 
positive PCR signal was invariably detected in 
PBPC samples of the 7 patients whose PB 
scored positive at PCR analysis. In 7 of the re-
maining 23 patients (30%) whose PB scored 
negative, PBPCs resulted positive at PCR analy-
sis. 
 
PB immunophenotyping: comparison with 
molecular data 
 
The predictive value of PB immunophenotyping 
was assessed at the time of PBPC harvest in the 
subgroup of mantle NHL patients by means of 
flow cytometry after staining with anti-CD5, anti-
CD19 and anti-CD23 monoclonal antibodies. 
The results of FACS and PCR analysis were com-
pared (Table 4): immunophenotyping was nega-
tive for presence of CD5+/CD19+ cells in 7 out 
of 9 patients (Figure 2A); however, in 2 of these 
patients (28%), PCR analysis was able to detect 
a signal corresponding to the presence of  lym-
phoma cells (Figure 2B). In the remaining 2 
cases, FACS analysis detected CD5+/CD19+ 
cells and PCR scored positive.  
 
Discussion 
 
Residual neoplastic lymphocytes in hematopoi-
etic progenitor cells reinfused in B-NHL patients 
during autologous transplantation may be an 
important cause of relapse. It has already been 
demonstrated by others that tumor cells con-
taminating BM harvest used in autologous 
transplantation can contribute to disease recur-
rence [4, 17, 18], and some recent reports indi-
cate that this may be true also when using 
PBPCs [19].  
 
Although BM and PB analysis at the end of the 
treatment has a well defined role in predicting 
lymphoma relapse [6], it is still a matter of de-
bate whether the same tissues are adequate for 
predicting MRD in PBPCs. Some recent papers 
have already given interesting insights about 
this isssue, although for different types of NHLs 
[20] or after different therapeutic strategies 
[21]. Thus, additional indications about this is-
sue may be helpful to prospectively guide PBPC 
harvesting procedures, in particular when ex-
vivo purging strategies have to be considered.  
 
In the present study, we tried to qualitatively 
evaluate if data obtained from BM and PB are 
predictive for the molecular status of PBPCs. To 
this aim, in a series of NHL patients who under-
went high-dose chemotherapy, we analyzed PB 
and BM samples obtained at the time of PBPC 
Table 3. Molecular analysis of BM, PB and 
PBPC 
Pt BM PBPC PB probe 
1 + - -   
2 + + -   
3 + - -   
4 + - -   
5 - - - bcl2 
6 + + -   
7 + + +   
8 - + -   
9 + + -   
10 + + +   
11 - - -   
12 + + +   
13 - - -   
14 - - -   
15 - + -   
16 - - - IGH 
17 - + -   
18 - - -   
19 - - -   
20 - - -   
21 - - -   
22 - + -   
23 - - -   
24 + + + bcl1 
25 + + +   
26 + - -   
27 - - -   
28 - - -   
29 + + + IGH 
30 - + +   
Neg: -; Pos: + 
 
Table 4. PB immunophenotyping vs. PCR 
Pt FACS PCR 
22 - - 
23 - - 
24 + + 
25 - + 
26 - - 
27 - - 
28 - - 
29 - + 
30 + + 
Neg: -; Pos: + 
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collection: among patients who had a PCR-
negative BM, 29% still had positive PBPCs. Dis-
cordance was also evident comparing data ob-
tained from PB and PBPCs: PCR-positive PBPCs 
were harvested in 30% of PCR-negative PB pa-
tients. In addition, the comparison of the results 
obtained by immunophenotyping and by PCR, 
showed that 2 out of 7 patients (28%) who 
scored negative at FACS analysis were found to 
have positive PB and PBPCs when analyzed by 
PCR. These findings question the value of PB 
immunophenotyping as a predictive assay for 
the evaluation of PBPCs. 
 
PCR amplification is widely being used to detect 
lymphoma cells in BM and PB. In this respect, 
our results confirm that at diagnosis, when tu-
mor burden is relevant, there is a concordance 
between BM and PB histological and molecular 
data, as reported by other groups [22]. How-
ever, a note of caution has to be made about 
the interpretation of these data when chemo-
therapy is administered: in this case, there is a 
decrease in tumor burden, blood-marrow barrier 
is altered [23] and cytokines probably modify 
the regulation of cell adhesion molecules [24, 
25]. In this situation PCR sensitivity becomes 
critical: in fact, depending on the marker used, 
the percentage of positive BM samples col-
lected after chemotherapy, at the time of PBPC 
harvest, could range from 66% (bcl-2/IgH or bcl-
1/IgH) to 16% (patient specific oligonucleotide). 
These data are in accordance with those ob-
tained by other groups [26]. 
 
In the case of a PCR-negative BM, harvesting 
PCR-positive PBPCs may have different explana-
tions such as i)an enrichment in neoplastic lym-
phocytes during PBPC harvest and ii)a negativity 
of BM samples for failure to aspirate the diag-
nostic cells due to residual reticulin fibrosis of-
ten associated with a lymphomatous infiltrate. 
However, it cannot be completely excluded that 
the detection of MRD in PBPCs may be due to 
the expansion and release in the bloodstream 
of the lymphoma cell population as a result of 
hematopoietic growth factor stimulation and 
their action on the growth rate and adhesion 
receptors of lymphoma cells as already sug-
gested by other authors [24, 25].  
 
An explanation for a PCR-negative PB patient 
whose harvest scores PCR-positive may be the 
administration of rituximab, sufficient to clear 
the former but not the latter from neoplastic 
cells. In this respect, it is thus not surprising 
that nearly 50% of these cases have a positive 
BM, since the clearance of B-cells might be 
more rapid in PB than in BM. 
 
Finally, an interesting issue that remains to be 
solved is about the cases with PCR-positive 
PBPCs who score negative both at BM and PB 
level (cases 8, 15, 17, 22): this could be due to 
Figure 2. FACS and 
PCR analysis of PB in 
mantle cell lymphoma 
patients at the time of 
PBPC harvest. A: flow 
cytometric characteri-
zation of PB; dot plots 
show the CD5/CD19 
distribution of B-
lymphocytes; B: PCR 
analysis of PB; pts 22 – 
26 were analyzed by 
bcl-1/IgH rearrange-
ment, pts 27 – 30 were 
analyzed by CDR3-
based oligonucleotides; 
MW, molecular weight 
standards; (+), positive 
control; (-), no DNA. 
Samples were analyzed 
on 1.5% agarose gel 
and stained with 
ethidium-bromide. 
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recruitment of neoplastic cells in PBPCs from 
other sites (i.e. spleen, liver) by unknown 
mechanism, in a way similar to intra-apheresis 
CD34+ cell recruitment described by some au-
thors [27]. 
 
Taken together our data suggest that, in pa-
tients with indolent and mantle cell NHL, bcl-2/
IgH and bcl-1/IgH PCR is superior to PCR based 
on CDIII sequences in terms of sensitivity, and 
that this technique has to be applied to PBPCs, 
and not to PB or BM, to assess neoplastic con-
tamination of the harvests. As the number of 
patients is small, final conclusions about the 
clinical importance of our findings awaits further 
study. In addition, in the near future, quantita-
tive rather than qualitative assays for the 
evaluation of MRD in PBPCs are desirable to 
evaluate and optimize chemo-immunotherapy 
protocols and PBPC mobilization regimens. 
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